Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer
NCT02136927 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33
Last updated 2019-05-03
Summary
Pharmacokinetic, bioequivalence study
Conditions
Interventions
- DRUG
-
SPARC1210
- DRUG
-
Reference1210
Sponsors & Collaborators
-
Sun Pharma Advanced Research Company Limited
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-08-31
- Primary Completion
- 2016-04-30
- Completion
- 2016-04-30
Countries
- India
Study Locations
More Related Trials
-
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
NCT06375707 ·Status: RECRUITING ·Phase: PHASE2
-
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
NCT05628870 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
NCT06957886 ·Status: RECRUITING ·Phase: PHASE3
-
Lynparza Breast Cancer Clinical Experience Investigation
NCT03590938 ·Status: COMPLETED
-
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
NCT04858997 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093 ·Status: RECRUITING ·Phase: PHASE3
-
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
NCT04478266 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
NCT07002177 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
NCT05792410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
NCT02894398 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
NCT00034125 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029 ·Status: RECRUITING ·Phase: PHASE1
-
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
NCT04394247 ·Status: COMPLETED
-
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
NCT05293964 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
NCT03839823 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT07235618 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
NCT00959946 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer
NCT07086196 ·Status: COMPLETED
-
Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer
NCT05244434 ·Status: WITHDRAWN ·Phase: NA
-
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
NCT03822468 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
NCT04296370 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559 ·Status: COMPLETED ·Phase: PHASE2